Vincristine sulfate

Catalog No.S1241 Synonyms: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Plk inhibitor cooperates with chemotherapeutic agents. Conditional patched mutant tumor cells were treated with increasing concentrations of the chemotherapeutic agents vincristine alone or in combination with 10 nMol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours.

    Cancer Research, 2013, 73(20): 6310-22 . Vincristine sulfate purchased from Selleck.

    for HXO-RB44 cells, IC50 values for VCR were changed in the different SG600 treatment groups. The results are representative of three independent  experiments and of f our replicates in each experiment.

    Int J Mol Sci 2012 13, 10736-10749 . Vincristine sulfate purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Targets
Microtubules [1]
(Cell-free assay)
32 μM
In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 M3nPfGNmdGxiVnnhZoltcXS7IFHzd4F6 MlvYNE0xNjVizszN MWCyOEBp NIL2[5pl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M2PMOVI2PjZ|N{[5
HepG2-HBV1.1 M4TQVmFxd3C2b4Ppd{BCe3OjeR?= MoPMNE0xNjVizszN NWHFRmpCOjRiaB?= NIrCO2RqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 NHz4ZXozPTZ4M{e2PS=>
HepG2.2.15 M1ezZmZ2dmO2aX;uJGF{e2G7 MnrrNE4yKM7:TR?= NVH4NHNDOjRiaB?= MmHydJJwdW:2ZYOgbIVx[XSrdHnzJGIhfmm{dYOgdJJwfGWrbjDlfJBz\XO|aX;u NE\kd4UzPTZ4M{e2PS=>
HepG2-HBV1.1 NYmzOm5OTnWwY4Tpc44hSXO|YYm= M4XYeVAvOSEQvF2= NHW0e|QzPCCq NHroVGpxem:vb4Tld{Bp\XCjdHn0bZMhSiC4aYL1d{Bxem:2ZXnuJIV5eHKnc4Ppc44> M1T6UlI2PjZ|N{[5
HepG2-HBV1.1 NHzHWZFHfW6ldHnvckBCe3OjeR?= Mm\5NE4yKM7:TR?= NUPvTXNoPDhiaB?= NF7DV|Vxem:vb4Tld{Bk\WyuIHX4Z5JmfGmxbjDv[kBp\XCjdHn0bZMhSiC4aYL1d{BvfWOuZX;jZZB{cWS|IHnud5Rm[WRib3[gbIVx[XSrdHnzJGIhfmm{dYOgSIFv\SCyYYL0bYNt\XN? NGDoV2kzPTZ4M{e2PS=>
HepG2-HBV1.1 MmnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTGNE4yKM7:TR?= Mo[5NU02KGR? M33LW4lvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJJRqdWViZHXw[Y5l\W62bIm= M1vsdVI2PjZ|N{[5
HepG2-HBV1.1 NYT5[o5nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[wMlEh|ryP M2fP[|EuPSCm M2jPVYlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJJRqdWViZHXw[Y5l\W62bIm= MXSyOVY3Ozd4OR?=
HepG2-HBV1.1 NEjIWIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVGwMlEh|ryP NInzengyOi15MjDo NIfGTW9qdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U> NUXlR4piOjV4NkO3Olk>
HepG2-HBV1.1 NHHIR|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFT1[4UxNjFizszN NWSw[IdlOTJvN{KgbC=> MornbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDheEBUNXCqYYPl MVWyOVY3Ozd4OR?=
Raji MVXGeY5kfGmxbjDBd5NigQ>? M1TrN|AvPcLizszN MnizO|IhcA>? NV;IW5Jq[WKxbHnzbIV{KGG3dH;wbIFogcLi NIHuTYMzPTR2NkO3Oy=>
SK-MEL-28  NGXHc|RHfW6ldHnvckBCe3OjeR?= M3eyWVMxKG6P MnHQOkBp MnvybY5lfWOnczDHNwKBm01iY3XscE1kgWOuZTDhdpJme3R? NETrfpAzPTNzM{CxNC=>
H157 M4TuNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1P0S2lEPTB;MT6wN{DDuSByLkC0JI1qfTKP NYnpcJF1OjV{NUe5NVE>
Jurkat Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnLUoRvOS1|IH7N NIjudFI1QMLiaB?= MkHFSG1UVw>? M1Pu[4Rm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk> NGH2eXYzPTF3NkG0Oi=>
CEM M4Ttd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3McIUyNTNibl2= NGXaZY01QMLiaB?= M4jPPWROW09? NWe5XYJX\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>? MmW2NlUyPTZzNE[=
P12 M4DxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWqxMVMhdk1? MmC0OFjDqGh? NGjsepZFVVOR NHK3[o1l\WO{ZXHz[ZMhfmmjYnzlJINmdGxiboXtZoVzeyCmb4PlJIRmeGWwZHXueIx6 MoWyNlUyPTZzNE[=
KB M4e0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHIfYtKSzVyPUCuNFA1QSEEsTCwMlAxODFizszN Mlz6NlUxPTh3Mk[=
KBv200 (ABCB1) MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq1V4VWUUN3ME2wMlM1PjJiwsGgNE4xODZ4IN88US=> NV7RV3NXOjVyNUi1NlY>
SUDHL6  MnL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUex5qCK|ryP NYmwRW8{PDhxN{KgbC=> M1LVWIlvcGmkaYTzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> M3vZXlI1QTZzNkC0
SUDHL6  Ml\NSpVv[3Srb36gRZN{[Xl? NEXzNJcy6oDLzszN MmfCO|IhcA>? NFrYfXBqdmS3Y3XzJJNq\26rZnnjZY51KGGyb4D0c5Rq[yCvb4LwbI9td2e7IHPoZY5o\XNiY3;0doV{fGWmIIfpeIghSkOOMUHBJJNqWk6D MlTONlQ6PjF4MES=
HCT-116 M336S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rubmdKPTB;NTDuUS=> Mn\pNlQ6Ojd6NUe=
SKNBe2C MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTN{LklCtVQvOCCwTR?= NVL4SmFtOjR7MkG5NlA>
IGNR91 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlW5TWM2OD1{ND6zxtEyNjdibl2= NFvJNIczPDl{MUmyNC=>
SKNAS M4i3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVy3S4hsUUN3ME2xMlXDuTBwMjDuUS=> MUeyOFkzOTl{MB?=
LAN1 NUXmRY1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof5TWM2OD1{LkRCtVAvOiCwTR?= MXiyOFkzOTl{MB?=
SHSY5Y NEjOW5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVK5d41UUUN3ME24MlLDuTBwNjDuUS=> MXeyOFkzOTl{MB?=
A549-WT MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTQe3ZnUUN3ME2xPU41OzdiwsGgNE42QTRiIH7N Mkf5NlQ5PTh6Mke=
A549-R M17OfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\Le|NGUUN3ME2xNk4yPzhiwsGgNE4{OzNiIH7N Ml33NlQ5PTh6Mke=
MCF-7-WT NV;hXpdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULPRY1qUUN3ME2xO{44PTJiwsGgNE4zOThiIH7N Mki3NlQ5PTh6Mke=
MCF-7-R M3TFXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml60TWM2OD13LkWzPUDDuSByLkG0OEAhdk1? NFnpPZEzPDh3OEiyOy=>
A549-R NETWNHdEgXSxdH;4bYNqfHliQYPzZZk> M{C4e2lEPTB;MUKuNVc5KMLzIECuN|M{KG6P MUOyOFg2QDh{Nx?=
MCF-7-R MYjDfZRwfG:6aXPpeJkhSXO|YYm= NEHWTZhKSzVyPUWuOVM6KMLzIECuNVQ1KG6P NVfQS2doOjR6NUi4Nlc>
SW620 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XROmlEPTB;Nz64NEDDuSByLkC4JI5O NGHoUI8zPDd{NkezPS=>
SW620/AD300 NXnoUYtVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnUTWM2OD17MEmuOlAhyrFiOD65NUBvVQ>? M3z5fFI1PzJ4N{O5
HEK293/pcDNA3.1 NWPUdlNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfN[HlVUUN3ME2xMlQ2KMLzIECuNlAhdk1? NHrwN4EzPDd{NkezPS=>
HEK293/ABCC1 Mn;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjsTWM2OD1zOT6yPUDDuSB{LkC4JI5O MVeyOFczPjd|OR?=
TCC NF3Bc5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPEW5QzPCCq NYT1UY5UUUN3ME23NEBvVQ>? NHXpVoUzPDdzNkm0OC=>
TCC M{j6Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUe0PEBp M3PleGlEPTB;NUCgcm0> M3nGUlI1PzF4OUS0
HepG2/ADM MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFq2cJFKSzVyPUKuO|g3O8LzMD6yN|cyKM7:TR?= MmLlNlQ4ODR3NU[=
HepG2 Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITlTXBKSzVyPUCuNFEyPcLzMD6wNFE4KM7:TR?= NGTq[XAzPDdyNEW1Oi=>
MCF-7/ADR MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\4cWNKSzVyPUSuOFgzPsLzMD6yNFcxKM7:TR?= MV2yOFcxPDV3Nh?=
MCF-7 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPUPFF[UUN3ME2wMlAyPToEsUCuNFA3OiEQvF2= NEH4cGQzPDdyNEW1Oi=>
A-172  M4G0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHxNE4yyqEQvF2= M1H1OFI1Nzd{IHi= NX:1b5pVcW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? M4\vfFI1PTNyMkO1
U-251MG NWrIUZZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LXZlAvOcLizszN MY[yOE84OiCq MYTpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 NEjV[YozPDV|MEKzOS=>
DLD-1 NVjFXXc6TnWwY4Tpc44hSXO|YYm= M1LBTFExOCCwTR?= MU[0PEBp M1LreZBzd22xdHXzJHJWVlh|IHTlcYV1cHmuYYTpc47DqA>? MWeyOFQxOzR3Mx?=
CCD18Co M13jTGZ2dmO2aX;uJGF{e2G7 MonJNVAxKG6P NFzndmg1QCCq NE\Leo1xem:vb4Tld{BTXU6[MzDk[Y1mfGi7bHH0bY9vyqB? NWTVd2lvOjR2MEO0OVM>
DLD-1 M2K5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml[3NE0yODByIH7N NIXrXI81QCCq Mn7tbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NG\QPYMzPDRyM{S1Ny=>
CCD18Co NGrTcIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NES2XXYxNTFyMECgcm0> NHqzWmU1QCCq M2jxSIlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NVX4SXBKOjR2MEO0OVM>
HepG2 NYewW2JOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LDNVI1KGh? NVniZ4ZuUUN3ME21Nk426oDLzszN MWCyOFM1OTZ6OB?=
HEK293/pcDNA3.1 NXO4ZmVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTxTWM2OD1yLkCwOOKyOC5yMECzJO69VQ>? MknvNlQzQDR5OEO=
HEK293/MRP1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwMEW1xtExNjBzMkCg{txO M2S0SFI1Ojh2N{iz
Ramos M2[yR2Fxd3C2b4Ppd{BCe3OjeR?= NVLGbZJoOuLCid88US=> MVO0PEBp M4HBR4lv\HWlZYOgN|QvPiYEsUGuPVImKGGyb4D0c5Nqew>? NVHmWJJoOjR{NU[0PVE>
NCI-H1299/pcDNA3 MmO1R4VtdCCYaXHibYxqfHliQYPzZZk> MWSwMVIxKG6P NILwXnA6PiCq MUHpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MWSyOFE4PzBzMh?=
H1299/ICAM-3 NX;wXYdRS2WubDDWbYFjcWyrdImgRZN{[Xl? M2nwUVAuOjBibl2= M17PNlk3KGh? MVfpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NEHPN2czPDF5N{CxNi=>
NCI-H1299/pcDNA3 M2G4PGZ2dmO2aX;uJGF{e2G7 NEnXb2gyNzVxMUCvNlDDqG6P NFXzfHE6PiCq NG\Ne3FqdmS3Y3XzJINt\WG4YXflJI9nKGOjc4Dhd4V{NTNuIEisJFktKGGwZDDQRXJR MWSyOFE4PzBzMh?=
H1299/ICAM-3 MVXGeY5kfGmxbjDBd5NigQ>? NUTBb2RtOS93L{GwM|IxyqCwTR?= NGfLcJQ6PiCq MXvpcoR2[2W|IHPs[YF3[WenIH;mJINie3Cjc3XzMVMtKDhuIEmsJIFv\CCSQWLQ MknlNlQyPzdyMUK=
W1 M2K5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfmSVVKSzVyPUCuNFA{OiEQvF2= NIPaTGEzPDF2MEG3Oi=>
W1VR NGHheoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLwTWM2OD1yLkC1OkDPxE1? MXyyOFE1ODF5Nh?=
K562 Ml;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMEOyJOKyKDBwMECxJEDPxE1? MmjYNlQyOzV7M{e=
K562/ADR MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjUeWlKSzVyPUOuNlYyKMLzIECuOFEzKM7:TR?= M1S1OFI1OTN3OUO3
K562 NV\MNlBbSXCxcITvd4l{KEG|c3H5 M1vtSFAvOyEQvF2= M{T1S|I1KGh? M1j1colv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? MWKyOFE{PTl|Nx?=
K562/ADR M1LDeGFxd3C2b4Ppd{BCe3OjeR?= NXWzeHNkOyEQvF2= MVKyOEBp MVfpcoR2[2W|IHHwc5B1d3Orcx?= M{fOOlI1OTN3OUO3
A549 NUnhW25RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITIN25KSzVyPUCuNVAhyrFiMD6wN{DPxE1? NX;iWYx7OjN7N{GwO|U>
K562 Mm[4R4VtdCCYaXHibYxqfHliQYPzZZk> MV2zMlc26oDVNkFCpI5O M4ezU|czyqCqwrC= M2HpVolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MUeyN|g4PzJ{Mx?=
lucena MXnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MXWzMlc26oDVNkFCpI5O MlPLO|LDqGkEoB?= M1X0O45wKGWoZnXjeC=> NV\scWlCOjN6N{eyNlM>
FEPS MmHIR4VtdCCYaXHibYxqfHliQYPzZZk> MlLsN{44PeLCk{[wxsBvVQ>? NGDjT4c4OsLiaNMg NITMVZJvdyCnZn\lZ5Q> NYHISJpYOjN6N{eyNlM>
A2780 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTmTWM2OD1|LkWgcW0> M{PFbVI{QDJ7MkCz
ACHN M{nJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRDBwMTDtUS=> MXyyN|gzQTJyMx?=
U-937 NHT2UpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfST5VKSzVyPEO0JI5O MVOyN|gzQTJyMx?=
Jurkat MWXBdI9xfG:|aYOgRZN{[Xl? M1PKU|XDqM7:Zz;tcOKh NYjTXZBvOjRiaB?= M1TKbYlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? MVuyN|gyODRyOR?=
Jurkat NV7LSoQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTxdGNNPcLizsznM41tyqB? MWOyOEBp NHLXZppienKnc4SgTpVzc2G2IHPlcIx{KGmwIFeyM20heGijc3W= MWeyN|gyODRyOR?=
Hep-2 NWCybohTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnKwTWM2OD1yLkC0xtExNjBzIN88US=> MUKyN|c5ODR{NB?=
Hep-2/v MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILZfotKSzVyPUGuPOKyOC5{MDFOwG0> M1\rbVI{PzhyNEK0
SGC-7901 MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Pv[|AuOTBizsznM41t M2LTS|I1NzR6L{eyJIg> NYqyfGpZcW6qaXLpeJMh[2WubDDndo94fGhiaX6g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz MV:yN|c1OzV5Mh?=
SGC-7901/VCR NGfjWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzYNHJkOC1zMDFOwIcwdWx? NGDScY4zPC92OD:3NkBp NFvWfYVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NY\kPJJYOjN5NEO1O|I>
SGC-7901 M4HMR2Fxd3C2b4Ppd{BCe3OjeR?= M1jYe4lv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? M3vj[|I{PzR|NUey
SGC-7901/VCR NXG0dGdsSXCxcITvd4l{KEG|c3H5 MX3pcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 MnHMNlM4PDN3N{K=
KB-3-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrySW1PUUN3ME2xMlY3KMLzIECuNVYzKM7:TR?= NFuzTVkzOzZ5M{S0OS=>
KB-C2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrI[pBKSzVyPUKwNk42PiEEsTC0Nk41QDFizszN M{TVTlI{Pjd|NES1
KB-3-1 M3OwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fqWmlEPTB;MT6yOkDDuSByLkCyO{DPxE1? NHv4VHczOzZ5M{S0OS=>
KB-V1 Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M375NGlEPTB;MkC4Mlg2KMLzIEKwMlQh|ryP M3f0OlI{Pjd|NES1
HEK293/pcDNA3.1 M1exUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XDPWlEPTB;MkSuNUDDuSByLkKwOEDPxE1? NWT2dnlMOjN4N{O0OFU>
HEK293/ABCB1 NFn6cJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTN3MUKuPEDDuSB|N{iuN|kyKM7:TR?= NFn5PVQzOzZ5M{S0OS=>
A549/EGFP  MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHuNE4xOS1zMECwJO69VQ>? Mk\0TWM2OD16Nj63JOKyKDJ7LkGg{txO MV[yN|Y{PDJ6Mh?=
A549/Slug NX[5To1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYKxTmZjOC5yMT2xNFAxKM7:TR?= M1\p[2lEPTB;OT63JOKyKDNwMTFOwG0> M2nOTlI{PjN2Mkiy
JFCR39  M{\qTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rwSFEhyrWP NXuzTZQxOjRiaB?= NGHBOXhFVVOR MmKzcYFzc2WmbImgbY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiR{KvUUBxcGG|ZTDj[Yxtew>? MnfNNlM2QTh{N{[=
A549 MUjGeY5kfGmxbjDBd5NigQ>? NEPxdmcyODBibl2= MUexOkBp MlzWSG1UVw>? MUjs[YFleyC2bzDhJIxwe3Nib3[gcYlkem:2dXL1cIV{ NFvFSlAzOzV7OEK3Oi=>
SGC7901 MmLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLDNlBZUUN3ME2xMlI36oDLwsJihKkxNjFzIN88[{9udA>? NIiwRZYzOzV4NES4Ni=>
SGC7901/LV-NC MnGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnxTWM2OD1zLke35qCKyrIkgJmwMlE3KM7:Zz;tcC=> Mm\iNlM2PjR2OEK=
SGC7901/LV-SGO1 NHH3PWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TJVGlEPTB;ND6zOwKBkcLz4pEJNE4{PyEQvHevcYw> NXHtXmFyOjN3NkS0PFI>
SGC7901/VCR MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;0TWM2Oz1{MD61N-KBkcLz4pEJNU46PiEQvHevcYw> NVXhWVBXOjN3NkS0PFI>
SGC7901/VCR-NC MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DFZmlEPTB;MUmuPFbjiIoEsfMAjVIvODFizsznM41t MoX4NlM2PjR2OEK=
SGC7901/VCR-si-SGO1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoraTWM2OD14LkG45qCKyrIkgJmxMlA{KM7:Zz;tcC=> NYLtVGp[OjN3NkS0PFI>
SGC7901/ADR M3jsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTdwOEZihKnDueLCiUCuOlQh|rypL33s M4PITVI{PTZ2NEiy
SGC7901/ADR-NC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[zTWM2OD16Lkmz5qCKyrIkgJmwMlY5KM7:Zz;tcC=> MmPFNlM2PjR2OEK=
SGC7901/ADR-si-SGO1 NHqwV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHzTWM2OD1|LkS25qCKyrIkgJmwMlI6KM7:Zz;tcC=> NYCxSYdnOjN3NkS0PFI>
SH-SY5Y  NX61eVgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrQdVJnOC5yMEGtNVAh|ryP NHrXOIszPCCq M3niSWlEPTB;MD6xNVPDuTBwMEGyJO69VQ>? NVPGdXBoOjNzMkmwOlU>
SH-SY5Y  M2DDVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHu2VWExNjByMT2xNEDPxE1? NXS2WGZqPDhiaB?= M{TFTmlEPTB;MD6wO|jDuTBwMEC5JO69VQ>? MVmyN|EzQTB4NR?=
SH-SY5Y  MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHOzXG8xNjByMT2xNEDPxE1? MkWzO|IhcA>? M37BVWlEPTB;MD6wOVHDuTBwMEC4JO69VQ>? NI\ifoYzOzF{OUC2OS=>
SH-SY5Y NIrRUVFCeG:ydH;zbZMhSXO|YYm= MkDiNE4yKM7:TR?= NX3vOmNxOC1{NDDo MonQbY5lfWOnczDhdI9xfG:|aYOgc4YhW0hvU2m1XUBk\WyuczDmc4xtd3erbnegZ4VtdCCleXPs[UBienKnc4SgZZQhfGinIFeyM20heGijc3W= NV3hXWx{OjNzMkmwOlU>
SH-SY5Y NVXURWgzSXCxcITvd4l{KEG|c3H5 MUKwMlEh|ryP MlXVNE0zPCCq NFTLNpFqdmS3Y3XzJI1qfG:2aXOgZZJz\XO2wrC= NIrsV4UzOzF{OUC2OS=>

... Click to View More Cell Line Experimental Data

In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: B16 melanoma cell
  • Concentrations: 10 nM
  • Incubation Time: 3 days
  • Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human rhabdomyosarcoma xenografts Rh12
  • Formulation: Water solutioin
  • Dosages: 3 mg/kg
  • Administration: A single i.p. administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 923.04
Formula

C46H58N4O14S

CAS No. 2068-78-2
Storage powder
Synonyms Leurocristine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03023358 Not yet recruiting Peripheral T Cell Lymphoma Nanfang Hospital of Southern Medical University February 2017 Phase 3
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT03003520 Recruiting Lymphoma, Large B-Cell, Diffuse Celgene February 2017 Phase 2
NCT03018626 Not yet recruiting Lymphoma, Large B-Cell, Diffuse Nanfang Hospital of Southern Medical University February 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • Answer:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Vincristine sulfate | Vincristine sulfate supplier | purchase Vincristine sulfate | Vincristine sulfate cost | Vincristine sulfate manufacturer | order Vincristine sulfate | Vincristine sulfate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID